TipRanks
Go Ultimate55% OFF

Compare Chugai Pharmaceutical Co (CUP) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:CUPChugai Pharmaceutical CoEUR 38.41EUR 63.59B22.291.40%Moderate BuyUnlock the DE:CUP analyst price target with TipRanks PremiumDE:CUPUnlock the DE:CUP top-analyst price target with TipRanks Premium
JP:4503Astellas PharmaJPY 2,571.00JPY 4.63T12.6260.69%NeutralUnlock the JP:4503 analyst price target with TipRanks PremiumDE:CUP vs JP:4503Unlock the JP:4503 top-analyst price target with TipRanks Premium
JP:4568Daiichi Sankyo CompanyJPY 2,754.00JPY 5.01T20.85-28.32%Strong BuyUnlock the JP:4568 analyst price target with TipRanks PremiumDE:CUP vs JP:4568Unlock the JP:4568 top-analyst price target with TipRanks Premium
JP:4523Eisai CoJPY 5,052.00JPY 1.42T33.6610.60%―Unlock the JP:4523 analyst price target with TipRanks PremiumDE:CUP vs JP:4523Unlock the JP:4523 top-analyst price target with TipRanks Premium
JP:4528ONO Pharmaceutical CoJPY 2,256.00JPY 1.06T14.2120.19%Moderate SellUnlock the JP:4528 analyst price target with TipRanks PremiumDE:CUP vs JP:4528Unlock the JP:4528 top-analyst price target with TipRanks Premium
JP:4502Takeda Pharmaceutical CoJPY 6,651.00JPY 10.62T27.1656.24%Strong BuyUnlock the JP:4502 analyst price target with TipRanks PremiumDE:CUP vs JP:4502Unlock the JP:4502 top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:CUPChugai Pharmaceutical Co38.41-0.86-2.19%
JP:4503Astellas Pharma2571.001008.6264.56%
JP:4568Daiichi Sankyo Company2754.00-802.20-22.56%
JP:4523Eisai Co5052.00628.7914.22%
JP:4528ONO Pharmaceutical Co2256.00439.6124.20%
JP:4502Takeda Pharmaceutical Co6651.002639.3265.79%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts